|
2019 Conference Publication Subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors for optimal tumor control and immune responses in vitro and in vivoOo, Zay Yar, Proctor, Martina, Stevenson, Alex, Nazareth, Deborah, Larsen, Jill, Haass, Nikolas and Gabrielli, Brian G. (2019). Subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors for optimal tumor control and immune responses in vitro and in vivo. AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta Ga, Mar 29-Apr 03, 2019. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.AM2019-1236 |
|
2019 Conference Publication Bortezomib-induced immunogenic cell death enhances immune response in melanomaDaignault, S. M., Ju, R., Spoerri, L., Stehbens, S. J., Hill, D. S., Gabrielli, B., Dolcetti, R. and Haass, N. K. (2019). Bortezomib-induced immunogenic cell death enhances immune response in melanoma. Society for Investigative Dermatology (SID) Meeting, Chicago, IL United States, 8-11 May 2019. London, United Kingdom: Nature Publishing Group. doi: 10.1016/j.jid.2019.03.907 |
|
2018 Journal Article Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancersShaikh, Mushfiq H., Idris, Adi, Johnson, Newell W., Fallaha, Sora, Clarke, Daniel T.W., Martin, David, Morgan, Iain M., Gabrielli, Brian and McMillan, Nigel A. J. (2018). Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers. Oral Oncology, 86, 105-112. doi: 10.1016/j.oraloncology.2018.09.006 |
|
2018 Journal Article Pathway dysregulation analysis of the nucleotide excision repair mechanisms reveals it is not a common feature of melanomasD’Arcy, Nicholas, Matigian, Nicholas, Lê Cao, Kim-Anh and Gabrielli, Brian (2018). Pathway dysregulation analysis of the nucleotide excision repair mechanisms reveals it is not a common feature of melanomas. Pigment Cell & Melanoma Research, 32 (2), 336-338. doi: 10.1111/pcmr.12740 |
|
2018 Journal Article CEP55 is a determinant of cell fate during perturbed mitosis in breast cancerKalimutho, Murugan, Sinha, Debottam, Jeffery, Jessie, Nones, Katia, Srihari, Sriganesh, Fernando, Winnie C., Duijf, Pascal H. G., Vennin, Claire, Raninga, Prahlad, Nanayakkara, Devathri, Mittal, Deepak, Saunus, Jodi M., Lakhani, Sunil R., López, J Alejandro, Spring, Kevin J., Timpson, Paul, Gabrielli, Brian, Waddell, Nicola and Khanna, Kum Kum (2018). CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Molecular Medicine, 10 (9) e8566. doi: 10.15252/emmm.201708566 |
|
2018 Journal Article Endogenous replication stress marks melanomas sensitive to CHEK1 inhibitors in vivoOo, Zay Yar, Stevenson, Alexander J., Proctor, Martina A., Daignault, Sheena M., Walpole, Sebastian, Lanagan, Catherine, Chen, James, Skalamera, Dubravka, Spoerri, Loredana, Ainger, Stephen, Sturm, Richard A, Haass, Nikolas K and Gabrielli, Brian (2018). Endogenous replication stress marks melanomas sensitive to CHEK1 inhibitors in vivo. Clinical Cancer Research, 24 (12), 2901-2912. doi: 10.1158/1078-0432.CCR-17-2701 |
|
2018 Journal Article Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivoStevenson, Alexander J., Ager, Eleanor I., Proctor, Martina A., Škalamera, Dubravka, Heaton, Andrew, Brown, David and Gabrielli, Brian G. (2018). Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Scientific Reports, 8 (1) 22882, 5144. doi: 10.1038/s41598-018-22882-w |
|
2018 Journal Article Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cellsLevrier, Claire, Rockstroh, Anja, Gabrielli, Brian, Kavallaris, Maria, Lehman, Melanie, Davis, Rohan A, Sadowski, Martin C and Nelson, Colleen C (2018). Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells. Cell Cycle, 17 (5), 652-668. doi: 10.1080/15384101.2017.1356512 |
|
2018 Journal Article Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancersHammerlindl, Heinz, Ravindran Menon, Dinoop, Hammerlindl, Sabrina, Emran, Abdullah Al, Torrano, Joachim, Sproesser, Katrin, Thakkar, Divya, Xiao, Min, Atkinson, Victoria G., Gabrielli, Brian, Haass, Nikolas K., Herlyn, Meenhard, Krepler, Clemens and Schaider, Helmut (2018). Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers. Clinical Cancer Research, 24 (5), 1090-1102. doi: 10.1158/1078-0432.CCR-16-2118 |
|
2018 Conference Publication Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanomaEmran, A., Marzese, D. M., Menon, D. R., Stark, M., Torrano, J., Hammerlindl, H., Zhang, G., Brafford, P., Hammerlindl, S., Gupta, D., Mills, G. B., Lu, Y., Flaherty, K., Sturm, R., Hoon, D. S. B., Gabrielli, B., Herlyn, M. and Schaider, H. (2018). Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma. Australasian College of Dermatologists, 51st Annual Scientific Meeting, Gold Coast, QLD, Australia , 19–22 May 2018. Richmond, VIC, Australia: Wiley-Blackwell Publishing. doi: 10.1111/ajd.16_12815 |
|
2018 Conference Publication Targeting cell cycle phase-specific drug sensitivity for melanoma therapyDaignault, S. M., Hill, D. S., Spoerri, L., Stehbens, S., Weninger, W., Gabrielli, B., Dolcetti, R. and Haass, N. K. (2018). Targeting cell cycle phase-specific drug sensitivity for melanoma therapy. 45th Annual Meeting of the Arbeitsgemeinscha-Dermatologische-Forschung (ADF), Zurich, Switzerland, 7-10 March 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2018 Conference Publication Overexpression of the cell cycle regulator Emi1 promotes chromosome instability and tumorigenesisDuijf, Pascal H. G., Vaidyanathan, Srividya, Cato, Kathleen, Thangavelu, Pulari U., Lin, Cheng-Yu, Tang, Lu, Pavey, Sandra, Haass, Nikolas K. and Gabrielli, Brian G. (2018). Overexpression of the cell cycle regulator Emi1 promotes chromosome instability and tumorigenesis. 76th Annual Meeting of the Japanese Cancer Association, Yokohama, Japan, 28-30 September 2017. Tokyo, Japan: Wiley Japan. doi: 10.1111/cas.13499 |
|
2017 Journal Article Distinct histone modifications denote early stress-induced drug tolerance in cancerEmran, Abdullah Al, Marzese, Diego M., Menon, Dinoop Ravindran, Stark, Mitchell S., Torrano, Joachim, Hammerlindl, Heinz, Zhang, Gao, Brafford, Patricia, Salomon, Matthew P., Nelson, Nellie, Hammerlindl, Sabrina, Gupta, Deepesh, Mills, Gordon B., Lu, Yiling, Sturm, Richard A., Flaherty, Keith, Hoon, Dave S. B., Gabrielli, Brian, Herlyn, Meenhard and Schaider, Helmut (2017). Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget, 9 (9), 8206-8222. doi: 10.18632/oncotarget.23654 |
|
2017 Journal Article Keratinocyte sonic hedgehog up-regulation drives the development of giant congenital nevi via paracrine endothelin-1 secretionChitsazan, Arash, Ferguson, Blake, Villani, Rehan, Handoko, Herlina Y, Mukhopadhyay, Pamela, Gabrielli, Brian, Mooi, Wolter J, Soyer, H Peter, Lambie, Duncan, Khosrotehrani, Kiarash, Morahan, Grant and Walker, Graeme J (2017). Keratinocyte sonic hedgehog up-regulation drives the development of giant congenital nevi via paracrine endothelin-1 secretion. The Journal of investigative dermatology, 138 (4), 893-902. doi: 10.1016/j.jid.2017.10.032 |
|
2017 Journal Article Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase InhibitorsMartin, David, Fallaha, Sora, Proctor, Martina, Stevenson, Alexander, Perrin, Lewis, McMillan, Nigel and Gabrielli, Brian (2017). Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors. Molecular Cancer Therapeutics, 16 (9), 1934-1941. doi: 10.1158/1535-7163.MCT-17-0159 |
|
2017 Journal Article Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunitiesHaass, Nikolas K. and Gabrielli, Brian (2017). Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities. Experimental Dermatology, 26 (7), 649-655. doi: 10.1111/exd.13303 |
|
2017 Journal Article Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanomaLee, Won Jae, Skalamera, Dubravka, Dahmer-Heath, Mareike, Shakhbazov, Konstanin, Ranall, Max V., Fox, Carly, Lambie, Duncan, Stevenson, Alexander J., Yaswen, Paul, Gonda, Thomas J. and Gabrielli, Brian (2017). Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma. SLAS Discovery, 22 (3), 298-308. doi: 10.1177/1087057116679592 |
|
2017 Conference Publication Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunitiesHaass, N., Spoerri, L., Tonnessen, C. A., Beaumont, K. A., Hill, D. S., Daignault, S. M., Gabrielli, B. and Weninger, W. (2017). Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities. Australasian College of Dermatologists 50th Annual Scientific Meeting, International Convention Centre, Sydney, NSW Australia, 6-9 May 2017. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/ajd.20_12652 |
|
2017 Journal Article 6α-Acetoxyanopterine: a novel structure class of mitotic inhibitor disrupting microtubule dynamics in prostate cancer cellsLevrier, Claire, Sadowski, Martin C., Rockstroh, Anja, Gabrielli, Brian, Kavallaris, Maria, Lehman, Melanie, Davis, Rohan A. and Nelson, Colleen C. (2017). 6α-Acetoxyanopterine: a novel structure class of mitotic inhibitor disrupting microtubule dynamics in prostate cancer cells. Molecular Cancer Therapeutics, 16 (1), 3-15. doi: 10.1158/1535-7163.MCT-16-0325 |
|
2017 Journal Article Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpointsD'Arcy, Nicholas and Gabrielli, Brian (2017). Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints. Current Medicinal Chemistry, 24 (15), 1504-1519. doi: 10.2174/0929867323666161205122613 |
